Related references
Note: Only part of the references are listed.Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study*
L. Gianni et al.
ANNALS OF ONCOLOGY (2022)
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Christina Yau et al.
LANCET ONCOLOGY (2022)
Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
Feng Ye et al.
BMC CANCER (2022)
Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials
Jeremy Braybrooke et al.
CANCER RESEARCH (2022)
Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis
Preethi John et al.
CLINICAL BREAST CANCER (2021)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2021)
Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
Pierre Loap et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2021)
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
Xingfa Huo et al.
BMC CANCER (2021)
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Neil T. Conlon et al.
BRITISH JOURNAL OF CANCER (2021)
Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients
Ramona Woitek et al.
CANCER RESEARCH (2021)
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
Xi Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
H. P. Eikesdal et al.
ANNALS OF ONCOLOGY (2021)
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report
Damian Smedley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer
Kelly E. Craven et al.
SCIENTIFIC REPORTS (2021)
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Julia Foldi et al.
NPJ BREAST CANCER (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics
Paul Roepman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2021)
A careful reassessment of anthracycline use in curable breast cancer
Sara Alsterlind Hurvitz et al.
NPJ BREAST CANCER (2021)
Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations
Anthony Bergeron et al.
MODERN PATHOLOGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
Vanessa Y. C. Sung et al.
NPJ BREAST CANCER (2021)
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai et al.
CANCER CELL (2021)
Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
Clinton Yam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer
Hope S. Rugo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile
Jean Berthelet et al.
SCIENCE ADVANCES (2021)
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial
Ke-Da Yu et al.
LANCET REGIONAL HEALTH-WESTERN PACIFIC (2021)
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population
Kassidy Beyerlin et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann et al.
CLINICAL CANCER RESEARCH (2020)
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)
Nadine Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T. Karn et al.
ANNALS OF ONCOLOGY (2020)
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
Ping Mei et al.
DIAGNOSTIC PATHOLOGY (2020)
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A. Jo Chien et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Junjie Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
Yuqin Ding et al.
PLOS ONE (2020)
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra et al.
NATURE COMMUNICATIONS (2020)
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial
Douglas Yee et al.
JAMA ONCOLOGY (2020)
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer A Phase 3 Randomized Clinical Trial
Ke-Da Yu et al.
JAMA ONCOLOGY (2020)
Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas
Xiangjie Sun et al.
MODERN PATHOLOGY (2020)
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Min Huang et al.
CANCER RESEARCH (2020)
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
Lin-Yu Xia et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution
Roxane M. Pommier et al.
NATURE COMMUNICATIONS (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
Luca Cavallone et al.
SCIENTIFIC REPORTS (2020)
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Dan Sha et al.
CANCER DISCOVERY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Karen Pinilla Alba et al.
CANCER RESEARCH (2020)
Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Katherine A. Hoadley et al.
CANCER RESEARCH (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes
Erin Pleasance et al.
NATURE CANCER (2020)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Oscar M. Rueda et al.
NATURE (2019)
A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses
Guillermo Prado-Vazquez et al.
SCIENTIFIC REPORTS (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.
Otto Metzger Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
Marie-Christine Caron et al.
NATURE COMMUNICATIONS (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Johan Staaf et al.
NATURE MEDICINE (2019)
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Andreas Schneeweiss et al.
EUROPEAN JOURNAL OF CANCER (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Priyanka Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
If we build it they will come: targeting the immune response to breast cancer
Margaret E. Gatti-Mays et al.
NPJ BREAST CANCER (2019)
Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Richard Schwab et al.
CANCER RESEARCH (2019)
mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC) Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial
S. Loibl et al.
CANCER RESEARCH (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer
E Obeid et al.
CANCER RESEARCH (2018)
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study
Reshma Jagsi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
J. A. Alberro et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Angela Santonja et al.
Oncotarget (2018)
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial
Luca Gianni et al.
JAMA ONCOLOGY (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
Jean Abraham et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS).
Stacy L. Moulder et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High speed of fork progression induces DNA replication stress and genomic instability
Apolinar Maya-Mendoza et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S. Loibl et al.
ANNALS OF ONCOLOGY (2018)
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
R. E. Coleman et al.
JOURNAL OF BONE ONCOLOGY (2018)
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL
Julia D. Wulfkuhle et al.
JCO PRECISION ONCOLOGY (2018)
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L. Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Cyclophosphamide and DocetaxelWith or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
Bent Ejlertsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
George S. Karagiannis et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer The Randomized Clinical FinXX Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results.
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
Tesa M. Severson et al.
BREAST CANCER RESEARCH (2017)
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Denise M. Wolf et al.
NPJ BREAST CANCER (2017)
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
Wendie D. den Brok et al.
JCO PRECISION ONCOLOGY (2017)
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
Maurizio Callari et al.
CLINICAL CANCER RESEARCH (2016)
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
D. Mavroudis et al.
ANNALS OF ONCOLOGY (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival
Peter Kern et al.
JOURNAL OF CHEMOTHERAPY (2016)
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Yi-Rong Liu et al.
BREAST CANCER RESEARCH (2016)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Fresia Pareja et al.
NPJ BREAST CANCER (2016)
Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc
William M. Sikov et al.
CANCER RESEARCH (2015)
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
Melinda L. Telli et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genomic landscape of adenoid cystic carcinoma of the breast
Luciano G. Martelotto et al.
JOURNAL OF PATHOLOGY (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M. Earl et al.
LANCET ONCOLOGY (2015)
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D. Bear et al.
LANCET ONCOLOGY (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.
Gunter Von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Predictive Factors and Patterns of Recurrence in Patients with Triple Negative Breast Cancer
Lauren Steward et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
A. Prat et al.
BRITISH JOURNAL OF CANCER (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial
Helena M. Earl et al.
LANCET ONCOLOGY (2014)
Genome-wide transcriptome profiling of homologous recombination DNA repair
Guang Peng et al.
NATURE COMMUNICATIONS (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Marieke A. Vollebergh et al.
BREAST CANCER RESEARCH (2014)
A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer NCCTG Study N0338
Vivek Roy et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
Justin M. Balko et al.
CANCER RESEARCH (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective
F. Penault-Llorca et al.
ANNALS OF ONCOLOGY (2012)
Neoadjuvant treatment of breast cancer
A. M. Thompson et al.
ANNALS OF ONCOLOGY (2012)
Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials
Nan Shao et al.
BREAST (2012)
Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer
Insuk Sohn et al.
GYNECOLOGIC ONCOLOGY (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Livio Trusolino et al.
CANCER DISCOVERY (2012)
Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
Nicolai J. Birkbak et al.
CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
D. G. Evans et al.
JOURNAL OF MEDICAL GENETICS (2011)
Elevated serum and tissue VEGF associated with poor outcome in breast cancer patients
Enas Mohamed Ali et al.
ALEXANDRIA JOURNAL OF MEDICINE (2011)
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
R. E. Coleman et al.
BRITISH JOURNAL OF CANCER (2010)
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Hannah Harrison et al.
CANCER RESEARCH (2010)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser et al.
CLINICAL CANCER RESEARCH (2010)
Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Luisa Bonilla et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Are circulating tumor cells predictive of overall survival?
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers
Francois Bertucci et al.
CANCER RESEARCH (2006)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
C Tognon et al.
CANCER CELL (2002)
Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902
JA van der Hage et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
